Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
The induction of resistance mechanisms represents an important problem for the targeted therapy of patients with non-small-cell lung cancer (NSCLC). The best-known resistance mechanism induced during treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is EGFR T79...
Main Author: | Paola Ulivi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/17/7/1186 |
Similar Items
-
NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
by: Estela Sánchez‐Herrero, et al.
Published: (2021-09-01) -
Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
by: Juan Zhou, et al.
Published: (2019-04-01) -
Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
by: Shafik Hanan Ezzat, et al.
Published: (2015-06-01) -
Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
by: Wang WX, et al.
Published: (2016-01-01) -
Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer
by: Yoshikane Nonagase, et al.
Published: (2019-10-01)